MX2021007502A - Formulaciones y métodos de vacuna de norovirus. - Google Patents

Formulaciones y métodos de vacuna de norovirus.

Info

Publication number
MX2021007502A
MX2021007502A MX2021007502A MX2021007502A MX2021007502A MX 2021007502 A MX2021007502 A MX 2021007502A MX 2021007502 A MX2021007502 A MX 2021007502A MX 2021007502 A MX2021007502 A MX 2021007502A MX 2021007502 A MX2021007502 A MX 2021007502A
Authority
MX
Mexico
Prior art keywords
methods
vaccine formulations
norovirus vaccine
vaccines
norovirus
Prior art date
Application number
MX2021007502A
Other languages
English (en)
Spanish (es)
Inventor
Taisei Masuda
James Sherwood
Paul Mendelman
Frank Baehner
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2021007502A publication Critical patent/MX2021007502A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2021007502A 2018-12-20 2019-12-20 Formulaciones y métodos de vacuna de norovirus. MX2021007502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782733P 2018-12-20 2018-12-20
PCT/US2019/067961 WO2020132510A1 (en) 2018-12-20 2019-12-20 Norovirus vaccine formulations and methods

Publications (1)

Publication Number Publication Date
MX2021007502A true MX2021007502A (es) 2021-10-13

Family

ID=71101884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007502A MX2021007502A (es) 2018-12-20 2019-12-20 Formulaciones y métodos de vacuna de norovirus.

Country Status (14)

Country Link
US (1) US20220054621A1 (enExample)
EP (1) EP3897712A4 (enExample)
JP (1) JP2022514759A (enExample)
KR (1) KR20210114941A (enExample)
CN (1) CN113453711A (enExample)
AR (1) AR117462A1 (enExample)
AU (1) AU2019404430A1 (enExample)
BR (1) BR112021012181A2 (enExample)
CA (1) CA3123860A1 (enExample)
CO (1) CO2021009379A2 (enExample)
IL (1) IL284233A (enExample)
MX (1) MX2021007502A (enExample)
SG (1) SG11202106628YA (enExample)
WO (1) WO2020132510A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
JPWO2024202045A1 (enExample) * 2023-03-31 2024-10-03
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006335256B2 (en) * 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) * 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP3299030B1 (en) * 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations

Also Published As

Publication number Publication date
US20220054621A1 (en) 2022-02-24
EP3897712A1 (en) 2021-10-27
EP3897712A4 (en) 2022-08-31
AU2019404430A1 (en) 2021-07-08
CN113453711A (zh) 2021-09-28
KR20210114941A (ko) 2021-09-24
BR112021012181A2 (pt) 2021-08-31
SG11202106628YA (en) 2021-07-29
AR117462A1 (es) 2021-08-04
CA3123860A1 (en) 2020-06-25
WO2020132510A1 (en) 2020-06-25
IL284233A (en) 2021-08-31
JP2022514759A (ja) 2022-02-15
CO2021009379A2 (es) 2021-08-30

Similar Documents

Publication Publication Date Title
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112017001796A2 (pt) composições de flagelina e seus usos
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CO2021009379A2 (es) Formulaciones y métodos de la vacuna contra el norovirus
EP4218807A3 (en) Zika virus vaccine
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
HK1254344A1 (zh) 抗原匹配的流感疫苗
EA201800148A1 (ru) Оспенная вакцина для лечения рака
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
PH12022550081A1 (en) Ehrlichia vaccines and immunogenic compositions
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
AU2019268149A1 (en) Live attenuated heterologous vaccine for Leptospira
MX2019015697A (es) Vacuna de subunidades anti-mycoplasma spp.
MX2019015695A (es) Vacuna de subunidades anti-mycoplasma spp.
MX2019015696A (es) Vacuna de subunidades anti-mycoplasma spp.
MX2019015698A (es) Vacuna de subunidades anti-mycoplasma spp.